News
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2025. Consolidated sales amounted to €2,992 million for the first nine months of 2025 versus €2,871 million for the prior-year period, representing a growth of +4.2% as reported.
Swipe to discover more
-
bioMérieux and Henry Ford Health host U.S. thought leaders on antimicrobial resistance to accelerate diagnostics-driven stewardship and policy
bioMérieux and Henry Ford Health partnered to host a Summit focused on promoting practical actions to address the threat posed by antimicrobial resistance. -
One step ahead of STEC - combatting the public health challenge of Shiga toxin-producing E. coli (STEC)
Escherichia coli (known as E. coli) are typically harmless bacteria that naturally occur in the intestines of humans and animals. Some strains of E. coli, however, can be incredibly harmful. One such strain is Shiga toxin-producing E. coli (STEC), which if ingested can create dangerous toxins that can lead to serious infections. -
bioMérieux publishes a Bioethics Charter: A first in the diagnostics sector
bioMérieux confirms its ethical commitment to clinical research through a Bioethics Charter that guarantees transparency, accountability, and respect for human dignity. In particular, it aims to protect research participants when collecting and using biological samples and personal data.
Enabling Decision-Making
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19